Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,372 questions · 3,874 findings · 666 reviews

No studies found 431 · 11.1%GRADE not reported 783 · 20.2%Very low 995 · 25.7%Low 909 · 23.5%Moderate 596 · 15.4%High 160 · 4.1%

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Death (all causes) · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in death (all causes) compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Graft loss including death · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in total graft loss (with death) compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Biopsy‐proven acute rejection · primary immunosuppression in kidney transplant recipients

Low probably leads to higher biopsy‐proven acute rejection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

CMV infection · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in CMV infection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Malignancy · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in all malignancy compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Number needing to change treatment · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in number needing to change treatment compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (low certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Diabetes · primary immunosuppression in kidney transplant recipients

Low probably leads to lower diabetes compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Lymphoma/PTLD · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in lymphoma/PTLD compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Acne/rash · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in acne/rash compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Hypercholesterolaemia · primary immunosuppression in kidney transplant recipients

Low probably leads to lower hypercholesterolaemia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Anaemia · primary immunosuppression in kidney transplant recipients

Low may leads to lower anaemia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Thrombocytopenia · primary immunosuppression in kidney transplant recipients

Low may leads to lower thrombocytopenia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).

1 finding from 1 review

Combined spinal‐epidural vs high‐dose spinal

Number of women requiring a repeat regional block or a general anaesthetic as a result of failure to establish adequate initial blockade · women undergoing caesarean section

Combined spinal‐epidural showed no clear difference in number of women requiring a repeat regional block or a general… compared with high‐dose spinal (low certainty).

1 finding from 1 review

Combined spinal‐epidural vs high‐dose spinal

Number of women requiring supplemental intra‐operative analgesia at any time after CSE or spinal anaesthetic insertion · women undergoing caesarean section

It is very uncertain whether combined spinal‐epidural changes number of women requiring supplemental intra‐operative analgesia at… compared with high‐dose spinal (very low certainty).

1 finding from 1 review

Combined spinal‐epidural vs high‐dose spinal

Number of women requiring intra‐operative conversion to general anaesthesia · women undergoing caesarean section

It is very uncertain whether combined spinal‐epidural changes number of women requiring intra‐operative conversion to general… compared with high‐dose spinal (very low certainty).

1 finding from 1 review